

**WHAT IS CLAIMED IS:**



1. A compound having the formula:



or a pharmaceutically acceptable salt thereof, wherein

A and B are each members independently selected from the group consisting of substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl;

X and Y are each members independently selected from the group consisting of:



with the proviso that at least one of X or Y is a bond, and wherein

the subscript m is 0, 1 or 2;

the subscript n is 1 or 2;


W is a member selected from the group consisting of O, N-OR<sup>5</sup>, N-NR<sup>1</sup>R<sup>2</sup>, N-NR<sup>1</sup>C(O)R<sup>6</sup> and N-OC(O)R<sup>6</sup>;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>5</sup> are each members independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl, aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, heteroaryl and heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>4</sup> is a member selected from the group consisting of H, OH, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, (C<sub>1</sub>-C<sub>6</sub>)acylamino, and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl; and



R<sup>6</sup> is a member selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl; and

M is a divalent linking group selected from the group consisting of:



wherein

U is a member selected from the group consisting of:



$\text{R}^7$  and  $\text{R}^8$  are each independently members selected from the group consisting of H, OH, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino;

$\text{R}^9$  is a member selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl, aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, heteroaryl and heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl;

$\text{R}^{10}$  is a member selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl and heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl; and



$\text{R}^{11}$  and  $\text{R}^{12}$  are members independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, C(O) $\text{R}^{14}$ , C(O)OR<sup>14</sup>, C(O)-NR<sup>14</sup>R<sup>15</sup>, S(O)<sub>2</sub>R<sup>13</sup> and S(O)<sub>2</sub>NR<sup>14</sup>R<sup>15</sup>;

wherein


$\text{R}^{13}$  is a member selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, phenyl and substituted phenyl; and

$\text{R}^{14}$  and  $\text{R}^{15}$  are each members independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl and (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl.

2. A compound of claim 1, wherein X and Y are independently selected from the group consisting of:



3. A compound of claim 1, wherein X and Y are each independently selected from the group consisting of:




3

1

2

4. A compound of claim 1, wherein X and Y are each independently selected from the group consisting of:



3

1


1

2

5. A compound of claim 1, wherein M is  $\begin{array}{c} \text{U} \quad \text{R}^7 \\ || \quad | \\ -\text{C}-\text{N}- \end{array}$  .

6. A compound of claim 1, wherein X and Y are each a bond, and M

is  $\begin{array}{c} \text{U} \quad \text{R}^7 \\ || \quad | \\ -\text{C}-\text{N}- \end{array}$  , wherein U is selected from the group consisting of



3

1

2

7. A compound of claim 6, wherein U is selected from the group consisting of




3

1

2

8. A compound of claim 1, said compound having the formula:




1                    9.     A compound of claim 8, wherein A is a phenyl group substituted  
2 with from one to three substituents selected from the group consisting of (C<sub>1</sub>-C<sub>4</sub>)alkyl,  
3 (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy, halogen, nitro, phenyl, naphthyl,  
4 pyrrolyl, pyrazolyl and -NR<sup>16</sup>R<sup>17</sup> wherein R<sup>16</sup> and R<sup>17</sup> are independently selected from  
5 the group consisting of hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl or are combined  
6 with the nitrogen atom to which each is attached to form a four-, five-, six- or seven-  
7 membered ring optionally having additional heteroatoms as ring members and optionally  
8 having additional substituents selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-  
9 C<sub>8</sub>)heteroalkyl and phenyl.

1                    10.    A compound of claim 8, wherein B is a phenyl group substituted  
2 with from one to three substituents selected from the group consisting of (C<sub>1</sub>-C<sub>4</sub>)alkyl,  
3 (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy, halogen, phenyl  
4 and phenoxy.

1                    11.    A compound of claim 8, wherein A is a phenyl group substituted  
2 with from one to three substituents selected from the group consisting of (C<sub>1</sub>-C<sub>4</sub>)alkyl,  
3 (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy, halogen and -NR<sup>16</sup>R<sup>17</sup> wherein R<sup>16</sup>  
4 and R<sup>17</sup> are independently selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl  
5 and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl or are combined with the nitrogen atom to which each is attached  
6 to form a four-, five-, six- or seven-membered ring optionally having additional  
7 heteroatoms as ring members and optionally having additional substituents selected from  
8 the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl and phenyl, and B is a phenyl  
9 group substituted with from one to three substituents selected from the group consisting  
10 of (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy,  
11 halogen, phenyl and phenoxy.

1                    12.    A compound of claim 8, wherein A is selected from the group  
2 consisting of substituted or unsubstituted thienyl, substituted or unsubstituted furanyl,  
3 substituted or unsubstituted indolyl, substituted or unsubstituted benzothienyl, substituted  
4 or unsubstituted benzothienyl, and radicals of the formulae:



5  
6           wherein  $R^{18}$  is a member selected from the group consisting of (C<sub>1</sub>-  
7 C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy and  
8 halogen.

1           **13.**   A compound of claim 8, wherein A is selected from the group  
2 consisting of substituted or unsubstituted benzofuranyl, substituted or unsubstituted  
3 benzothienyl, substituted or unsubstituted indolyl, substituted or unsubstituted  
4 benzimidazolyl, substituted or unsubstituted benzthiazolyl and substituted or  
5 unsubstituted benzoxazolyl.

1           **14.**   A method of reducing bacterial growth on a surface, said method  
2 comprising contacting said surface with a compound of claim 1.



1                    15.    A method of treating a bacterial infection comprising contacting a  
2    subject in need of such treatment with an effective amount of a compound having the  
3    formula:



4  
5    or a pharmaceutically acceptable salt thereof, wherein

6            A and B are each members independently selected from the group consisting of  
7            substituted and unsubstituted aryl and substituted and unsubstituted  
8            heteroaryl;

9            X and Y are each members independently selected from the group consisting of:



10

11            with the proviso that at least one of X or Y is a bond, and wherein

12            the subscript m is 0, 1 or 2;

13            the subscript n is 1 or 2;


14            W is a member selected from the group consisting of O, N-OR<sup>5</sup>, N-NR<sup>1</sup>R<sup>2</sup>,  
15            N-NR<sup>1</sup>C(O)R<sup>6</sup> and N-OC(O)R<sup>6</sup>;

16            R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> are each members independently selected from the group  
17            consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl, aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, heteroaryl and  
18            heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl;

19            R<sup>4</sup> is a member selected from the group consisting of H, OH, (C<sub>1</sub>-C<sub>6</sub>)alkyl,  
20            (C<sub>1</sub>-C<sub>6</sub>)alkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino,  
21            (C<sub>1</sub>-C<sub>6</sub>)acylamino, and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl; and

22            R<sup>6</sup> is a member selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-  
23            C<sub>6</sub>)alkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino and  
24            (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl; and


25            M is a divalent linking group selected from the group consisting of:



26



27            wherein

28            U is a member selected from the group consisting of:



$R^7$  and  $R^8$  are each members independently selected from the group consisting of H, OH, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino;  
 $R^9$  is a member selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl, aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, heteroaryl and heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl;  
 $R^{10}$  is a member selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl and heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl; and  
 $R^{11}$  and  $R^{12}$  are members independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, C(O) $R^{14}$ , C(O)OR<sup>14</sup>, C(O)-NR<sup>14</sup>R<sup>15</sup>, S(O)<sub>2</sub>R<sup>13</sup> and S(O)<sub>2</sub>NR<sup>14</sup>R<sup>15</sup>;  
 wherein  
 $R^{13}$  is a member selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, phenyl and substituted phenyl; and  
 $R^{14}$  and  $R^{15}$  are each members independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl and (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl.

**16.** A method in accordance with claim 15, wherein X and Y are independently selected from the group consisting of:



**17.** A method in accordance with claim 15, wherein X and Y are each independently selected from the group consisting of:

a bond ,  $\begin{array}{c} \text{---C---} \\ \parallel \\ \text{W} \end{array}$  and  $\begin{array}{c} \text{---C---} \\ \diagup \quad \diagdown \\ \text{R}^2 \quad \text{R}^4 \end{array}$


3

1

18. A method in accordance with claim 15, wherein X and Y are each a

2

bond, and M is  $\begin{array}{c} \text{U} \quad \text{R}^7 \\ \parallel \quad | \\ \text{---C---N---} \end{array}$ , wherein U is selected from the group consisting of




3

1

19. A method in accordance with claim 15, said compound having the

2

formula:



3

1

20. A method in accordance with claim 19, wherein A is a phenyl

2

group substituted with from one to three substituents selected from the group consisting

3

of (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy, halogen, nitro,

4

phenyl, naphthyl, pyrrolyl, pyrazolyl and -NR<sup>16</sup>R<sup>17</sup> wherein R<sup>16</sup> and R<sup>17</sup> are

5

independently selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl and (C<sub>1</sub>-

6

C<sub>8</sub>)heteroalkyl or are combined with the nitrogen atom to which each is attached to form

7

a four-, five-, six- or seven-membered ring optionally having additional heteroatoms as

8

ring members and optionally having additional substituents selected from the group

9

consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl and phenyl.

1

21. A method in accordance with claim 19, wherein B is a phenyl

2

group substituted with from one to three substituents selected from the group consisting

3

of (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy,

4

halogen, phenyl and phenoxy.

1

22. A method in accordance with claim 19, wherein A is a phenyl


2

group substituted with from one to three substituents selected from the group consisting



3 of (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy, halogen and –  
4 NR<sup>16</sup>R<sup>17</sup> wherein R<sup>16</sup> and R<sup>17</sup> are independently selected from the group consisting of  
5 hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl or are combined with the nitrogen atom to  
6 which each is attached to form a four-, five-, six- or seven-membered ring optionally  
7 having additional heteroatoms as ring members and optionally having additional  
8 substituents selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl and  
9 phenyl, and B is a phenyl group substituted with from one to three substituents selected  
10 from the group consisting of (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, (C<sub>1</sub>-  
11 C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy, halogen, phenyl and phenoxy.

1                   **23.**     A method in accordance with claim **19**, wherein A is selected from  
2 the group consisting of substituted or unsubstituted thienyl, substituted or unsubstituted  
3 furanyl, substituted or unsubstituted indolyl, substituted or unsubstituted benzothienyl,  
4 substituted or unsubstituted benzothienyl, and radicals of the formulae:



5  
6 wherein  $R^{18}$  is a member selected from the group consisting of (C<sub>1</sub>-  
7 C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy and  
8 halogen.

1           **24.** A method in accordance with claim **23**, wherein A is selected from  
2 the group consisting of substituted or unsubstituted benzofuranyl, substituted or  
3 unsubstituted benzothienyl, substituted or unsubstituted indolyl, substituted or  
4 unsubstituted benzimidazolyl, substituted or unsubstituted benzthiazolyl and substituted  
5 or unsubstituted benzoxazolyl.



1           **25.** A composition comprising a pharmaceutically acceptable excipient  
2 in admixture with a compound having the formula:



or a pharmaceutically acceptable salt thereof, wherein

A and B are each members independently selected from the group consisting of substituted and unsubstituted aryl and substituted and unsubstituted heteroaryl;

X and Y are each members independently selected from the group consisting of:



with the proviso that at least one of X or Y is a bond, and wherein

the subscript m is 0, 1 or 2;

the subscript n is 1 or 2;


W is a member selected from the group consisting of O, N-OR<sup>5</sup>, N-NR<sup>1</sup>R<sup>2</sup>, N-NR<sup>1</sup>C(O)R<sup>6</sup> and N-OC(O)R<sup>6</sup>;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> are each members independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl, aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, heteroaryl and heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>4</sup> is a member selected from the group consisting of H, OH, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, (C<sub>1</sub>-C<sub>6</sub>)acylamino, and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl; and


R<sup>6</sup> is a member selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl; and

M is a divalent linking group selected from the group consisting of:




wherein

U is a member selected from the group consisting of:



$R^7$  and  $R^8$  are each members independently selected from the group consisting of H, OH, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino;  
 $R^9$  is a member selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl, aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, heteroaryl and heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl;  
 $R^{10}$  is a member selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl and heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl; and  
 $R^{11}$  and  $R^{12}$  are members independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, C(O) $R^{14}$ , C(O)OR<sup>14</sup>, C(O)-NR<sup>14</sup>R<sup>15</sup>, S(O)<sub>2</sub>R<sup>13</sup> and S(O)<sub>2</sub>NR<sup>14</sup>R<sup>15</sup>;  
 wherein  
 $R^{13}$  is a member selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl, phenyl and substituted phenyl; and  
 $R^{14}$  and  $R^{15}$  are each members independently selected from the group consisting of H, (C<sub>1</sub>-C<sub>6</sub>)alkyl and (C<sub>1</sub>-C<sub>6</sub>)heteroalkyl.

**26.** A composition in accordance with claim **25**, wherein X and Y are independently selected from the group consisting of:




**27.** A composition in accordance with claim **25**, wherein X and Y are each independently selected from the group consisting of:

a bond ,  $\begin{array}{c} \text{---C---} \\ \text{W} \end{array}$  and  $\begin{array}{c} \text{---C---} \\ \text{R}^2 \text{ R}^4 \end{array}$  .

3


1                    28.    A composition in accordance with claim 25, wherein X and Y are

2    each a bond, and M is  $\begin{array}{c} \text{U} \quad \text{R}^7 \\ \text{---C---N---} \end{array}$  , wherein U is selected from the group consisting of



3

1                    29.    A composition in accordance with claim 25, said compound having  
2    the formula:




3

1                    30.    A composition in accordance with claim 29, wherein A is a phenyl  
2    group substituted with from one to three substituents selected from the group consisting  
3    of (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy, halogen, nitro,  
4    phenyl, naphthyl, pyrrolyl, pyrazolyl and -NR<sup>16</sup>R<sup>17</sup> wherein R<sup>16</sup> and R<sup>17</sup> are  
5    independently selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl and (C<sub>1</sub>-  
6    C<sub>8</sub>)heteroalkyl or are combined with the nitrogen atom to which each is attached to form  
7    a four-, five-, six- or seven-membered ring optionally having additional heteroatoms as  
8    ring members and optionally having additional substituents selected from the group  
9    consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl and phenyl.

1                    31.    A composition in accordance with claim 29, wherein B is a phenyl  
2    group substituted with from one to three substituents selected from the group consisting  
3    of (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy,  
4    halogen, phenyl and phenoxy.

1                   **32.**     A composition in accordance with claim **29**, wherein A is a phenyl  
2     group substituted with from one to three substituents selected from the group consisting  
3     of (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy, halogen and –  
4     NR<sup>16</sup>R<sup>17</sup> wherein R<sup>16</sup> and R<sup>17</sup> are independently selected from the group consisting of  
5     hydrogen, (C<sub>1</sub>-C<sub>8</sub>)alkyl and (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl or are combined with the nitrogen atom to  
6     which each is attached to form a four-, five-, six- or seven-membered ring optionally  
7     having additional heteroatoms as ring members and optionally having additional  
8     substituents selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>8</sub>)heteroalkyl and  
9     phenyl, and B is a phenyl group substituted with from one to three substituents selected  
10    from the group consisting of (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)heteroalkyl, (C<sub>1</sub>-  
11    C<sub>4</sub>)haloalkyl, (C<sub>1</sub>-C<sub>4</sub>)haloalkoxy, halogen, phenyl and phenoxy.

1                   **33.**     A composition in accordance with claim **29**, wherein A is selected  
2     from the group consisting of substituted or unsubstituted thienyl, substituted or  
3     unsubstituted furanyl, substituted or unsubstituted indolyl, substituted or unsubstituted  
4     benzothienyl, substituted or unsubstituted benzothienyl, and radicals of the formulae:



1                   **34.**     A composition in accordance with claim **33**, wherein A is selected  
2     from the group consisting of substituted or unsubstituted benzofuranyl, substituted or  
3     unsubstituted benzothienyl, substituted or unsubstituted indolyl, substituted or  
4     unsubstituted benzimidazolyl, substituted or unsubstituted benzthiazolyl and substituted  
5     or unsubstituted benzoxazolyl.